What’s the current market cap for Aura Biosciences stock?

Aura Biosciences (AURA) has a market cap of $675m as of June 11, 2026.

What is the P/E ratio for Aura Biosciences stock?

The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of June 11, 2026.

Does Aura Biosciences stock pay dividends?

No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of June 11, 2026.

When is the next Aura Biosciences dividend payment date?

Aura Biosciences (AURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Aura Biosciences?

Aura Biosciences (AURA) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Aura Biosciences stock | $AURA Share Price

13:30

15:10

16:45

18:25

20:00

About Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Ticker

$AURA

Sector

Health

Primary listing

NASDAQ

Employees

113

Headquarters

Boston, United States

Website

www.aurabiosciences.com

Aura Biosciences Metrics

BasicAdvanced

$675m

-$1.74

0.37

What the Analysts think about Aura Biosciences

Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.

Bulls say / Bears say

A strong cash position of $144.2 million as of December 31, 2025 extends the runway into Q1 2027, supporting the ongoing development of the bel-sar Phase 3 CoMpass trial. (GlobeNewswire)

Successful closing of a $299 million public offering on May 5, 2026, including the full exercise of the underwriters’ option, greatly boosts liquidity for upcoming trial milestones. (GlobeNewswire)

Faster enrollment in the global Phase 3 CoMpass trial, on track to finish by mid-2026 under an FDA Special Protocol Assessment, helps secure the timeline for topline data expected in H2 2027. (GlobeNewswire)

Research and development expenses increased 23% to $90.3 million in FY2025, raising cash burn ahead of expected regulatory milestones. (GlobeNewswire)

Marketable securities fell about 29% year-over-year to $84.7 million as of December 31, 2025, showing depletion of liquid assets even after recent financing. (GlobeNewswire)

Net loss widened to $106.2 million in FY2025 from $86.9 million in FY2024, underscoring the company’s ongoing lack of revenue and reliance on outside funding. (GlobeNewswire)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Aura Biosciences Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Aura Biosciences Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AURA

Capital at risk

Market closed

Upcoming events

No upcoming events